Prascend 1 mg Tablets for Horses

AN: 01122/2025Page 4 of 7
The veterinary medicinal product should be administered, once daily.
To facilitate administration, the required daily dose should be placed in a small amount
of water and/or mixed with molasses or other sweetener and agitated until dissolved. In
this case, the dissolved tablets should be administered with a syringe. The whole
amount should be administered immediately. Tablets should not be crushed. Do not use
the veterinary medicinal product if you notice visible signs of deterioration or if the
blister is breached.
Starting dose
The starting dose is 2 µg pergolide/kg (dose range: 1.3 to 2.4 µg/kg) body weight.
Studies from the published literature cite the most common, average dose as 2 µg
pergolide/kg with a range from 0.6 to 10 µg pergolide/kg (0.25 to 5 mg total daily dose
per horse). The starting dose (2 µg pergolide/kg) should then be titrated according to
the individual response as determined by monitoring (see below).
Starting doses are recommended as follows:
Horse body weightNumber of tabletsStarting doseDosage range200 - 400 kg½0.5 mg1.3 - 2.5 μg/kg401 - 600 kg11.0 mg1.7 - 2.5 µg/kg601 - 850 kg1 ½1.5 mg1.8 - 2.5 µg/kg851 - 1000 kg22.0 mg2.0 - 2.4 µg/kg
Maintenance dose
Life long treatment is anticipated for this disease.
Most horses respond to therapy and are stabilised at an average dose of 2 µg
pergolide/kg body weight. Clinical improvement with pergolide is expected within 6 to 12
weeks. Horses may respond clinically at lower or varying doses; it is therefore
recommended to titrate to the lowest effective dose per individual based on response to
therapy, whether it is effectiveness or signs of intolerance. Some horses may require
doses as high as 10 µg pergolide/kg body weight per day. In these rare situations,
appropriate additional monitoring is advised.
Following initial diagnosis, repeat endocrinologic testing for dose titration and
monitoring of treatment at intervals of 4 to 6 weeks until stabilisation or improvement of
clinical signs and/or diagnostic testing occurs.
Clinical signs are: hypertrichosis, polyuria, polydipsia, muscle wasting, abnormal fat
distribution, chronic infections, laminitis, sweating, etc.
The approach to treatment is the dose titration to the lowest effective dose per
individual, based on response to therapy, whether it is effectiveness or signs of
intolerance. Depending on the severity of the disease, time to treatment response may
vary among individuals.
If clinical signs or diagnostic testing have not yet improved at the first 4 to 6 week
interval, the total daily dose may be increased by 0.5 mg. In case clinical signs have
improved but are not yet normalised, the veterinarian may decide to titrate or not to
titrate the dose, considering the individual’s response/tolerance to the dose.
In case clinical signs are not adequately controlled (clinical evaluation and/or diagnostic
testing) it is recommended to increase the total daily dose by 0.5 mg increments every 4
to 6 weeks until stabilisation occurs and if the drug is tolerated at that dose.
AN: 01122/2025Page 5 of 7
If signs of dose intolerance develop, treatment should be stopped for 2 to 3 days and
reinstated at one-half of the previous dose. The total daily dose may then be titrated
back up to the desired clinical effect by 0.5 mg increments every 2 to 4 weeks. If a dose
is missed, the next scheduled dose should be administered as prescribed.
Following stabilisation, regular clinical assessment and diagnostic testing should be
performed every 6 months to monitor treatment and dose. Where there is no apparent
response to treatment, the diagnosis should be re-evaluated.